Analysis of pol integrase sequences in diverse HIV type 1 strains using a prototype genotyping assay

Susan Eshleman, Sarah E. Hudelson, Peter Smith, John Hackett, Vera Holzmayer, Priscilla Swanson, Sushil G. Devare, Natalia Marlowe

Research output: Contribution to journalArticle

Abstract

A prototype assay was used to genotype integrase (IN) from 120 HIV-1- infected IN inhibitor-naive adults from Argentina, Brazil, Cameroon, South Africa, Thailand, and Uganda. Subtype designations based on analysis of pol IN sequences were A (14), B (15), C (12), D (11), F (12), G (7), H (1), CRF01-AE (9), CRF02-AG (34), CRF22-01 A1 (4), and CRF37-cpx (1). Ten (8.3%) of 120 samples had mutations associated with reduced susceptibility to the IN inhibitors, raltegravir and elvitegravir. Two samples had E92Q (both subtype B) and eight had E157Q (2A, 1C, 1D, 1F, 3 CRF02-AG). Some samples had other mutations selected by these drugs including T97A, and some had amino acid polymorphisms at positions associated with raltegravir and elvitegravir resistance. Mutations associated with other investigational HIV IN inhibitors were also identified. This suggests that HIV strains may vary in their natural susceptibility to HIV IN inhibitors.

Original languageEnglish (US)
Pages (from-to)343-345
Number of pages3
JournalAIDS Research and Human Retroviruses
Volume25
Issue number3
DOIs
StatePublished - Mar 1 2009

Fingerprint

Integrases
HIV Integrase Inhibitors
Integrase Inhibitors
HIV-1
Mutation
Cameroon
Uganda
Argentina
Thailand
South Africa
Brazil
Genotype
HIV
Amino Acids
Pharmaceutical Preparations
Raltegravir Potassium
JTK 303

ASJC Scopus subject areas

  • Immunology
  • Virology
  • Infectious Diseases

Cite this

Analysis of pol integrase sequences in diverse HIV type 1 strains using a prototype genotyping assay. / Eshleman, Susan; Hudelson, Sarah E.; Smith, Peter; Hackett, John; Holzmayer, Vera; Swanson, Priscilla; Devare, Sushil G.; Marlowe, Natalia.

In: AIDS Research and Human Retroviruses, Vol. 25, No. 3, 01.03.2009, p. 343-345.

Research output: Contribution to journalArticle

Eshleman, S, Hudelson, SE, Smith, P, Hackett, J, Holzmayer, V, Swanson, P, Devare, SG & Marlowe, N 2009, 'Analysis of pol integrase sequences in diverse HIV type 1 strains using a prototype genotyping assay', AIDS Research and Human Retroviruses, vol. 25, no. 3, pp. 343-345. https://doi.org/10.1089/aid.2008.0236
Eshleman, Susan ; Hudelson, Sarah E. ; Smith, Peter ; Hackett, John ; Holzmayer, Vera ; Swanson, Priscilla ; Devare, Sushil G. ; Marlowe, Natalia. / Analysis of pol integrase sequences in diverse HIV type 1 strains using a prototype genotyping assay. In: AIDS Research and Human Retroviruses. 2009 ; Vol. 25, No. 3. pp. 343-345.
@article{567afeb222354c37b7a167034dc79150,
title = "Analysis of pol integrase sequences in diverse HIV type 1 strains using a prototype genotyping assay",
abstract = "A prototype assay was used to genotype integrase (IN) from 120 HIV-1- infected IN inhibitor-naive adults from Argentina, Brazil, Cameroon, South Africa, Thailand, and Uganda. Subtype designations based on analysis of pol IN sequences were A (14), B (15), C (12), D (11), F (12), G (7), H (1), CRF01-AE (9), CRF02-AG (34), CRF22-01 A1 (4), and CRF37-cpx (1). Ten (8.3{\%}) of 120 samples had mutations associated with reduced susceptibility to the IN inhibitors, raltegravir and elvitegravir. Two samples had E92Q (both subtype B) and eight had E157Q (2A, 1C, 1D, 1F, 3 CRF02-AG). Some samples had other mutations selected by these drugs including T97A, and some had amino acid polymorphisms at positions associated with raltegravir and elvitegravir resistance. Mutations associated with other investigational HIV IN inhibitors were also identified. This suggests that HIV strains may vary in their natural susceptibility to HIV IN inhibitors.",
author = "Susan Eshleman and Hudelson, {Sarah E.} and Peter Smith and John Hackett and Vera Holzmayer and Priscilla Swanson and Devare, {Sushil G.} and Natalia Marlowe",
year = "2009",
month = "3",
day = "1",
doi = "10.1089/aid.2008.0236",
language = "English (US)",
volume = "25",
pages = "343--345",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Analysis of pol integrase sequences in diverse HIV type 1 strains using a prototype genotyping assay

AU - Eshleman, Susan

AU - Hudelson, Sarah E.

AU - Smith, Peter

AU - Hackett, John

AU - Holzmayer, Vera

AU - Swanson, Priscilla

AU - Devare, Sushil G.

AU - Marlowe, Natalia

PY - 2009/3/1

Y1 - 2009/3/1

N2 - A prototype assay was used to genotype integrase (IN) from 120 HIV-1- infected IN inhibitor-naive adults from Argentina, Brazil, Cameroon, South Africa, Thailand, and Uganda. Subtype designations based on analysis of pol IN sequences were A (14), B (15), C (12), D (11), F (12), G (7), H (1), CRF01-AE (9), CRF02-AG (34), CRF22-01 A1 (4), and CRF37-cpx (1). Ten (8.3%) of 120 samples had mutations associated with reduced susceptibility to the IN inhibitors, raltegravir and elvitegravir. Two samples had E92Q (both subtype B) and eight had E157Q (2A, 1C, 1D, 1F, 3 CRF02-AG). Some samples had other mutations selected by these drugs including T97A, and some had amino acid polymorphisms at positions associated with raltegravir and elvitegravir resistance. Mutations associated with other investigational HIV IN inhibitors were also identified. This suggests that HIV strains may vary in their natural susceptibility to HIV IN inhibitors.

AB - A prototype assay was used to genotype integrase (IN) from 120 HIV-1- infected IN inhibitor-naive adults from Argentina, Brazil, Cameroon, South Africa, Thailand, and Uganda. Subtype designations based on analysis of pol IN sequences were A (14), B (15), C (12), D (11), F (12), G (7), H (1), CRF01-AE (9), CRF02-AG (34), CRF22-01 A1 (4), and CRF37-cpx (1). Ten (8.3%) of 120 samples had mutations associated with reduced susceptibility to the IN inhibitors, raltegravir and elvitegravir. Two samples had E92Q (both subtype B) and eight had E157Q (2A, 1C, 1D, 1F, 3 CRF02-AG). Some samples had other mutations selected by these drugs including T97A, and some had amino acid polymorphisms at positions associated with raltegravir and elvitegravir resistance. Mutations associated with other investigational HIV IN inhibitors were also identified. This suggests that HIV strains may vary in their natural susceptibility to HIV IN inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=65449116538&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65449116538&partnerID=8YFLogxK

U2 - 10.1089/aid.2008.0236

DO - 10.1089/aid.2008.0236

M3 - Article

VL - 25

SP - 343

EP - 345

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 3

ER -